No Picture
Trading Ideas

Lululemon Is on Fire This Holiday Season

With the start of trading today, we’ve now entered into a time period that’s been historically very, very bullish.
For instance, from the close of trading tomorrow until the end of next Friday (which includes Black Friday and Cyber Monday), the S&P 500 has been positive in 58 out of the last 69 years – which is an amazing 84% positive rating.
As for the down years, only four have seen declines of more than 1% (1951, 1987, 2009 and 2011).
I find this interesting because this historically strong market period is coming at a time when we’ve seen both huge upside moves …read more […]

No Picture
Trading Ideas

UPDATE 1-FDA approves Global Blood Therapeutics's sickle cell disease drug

The U.S. Food and Drug Administration said on Monday it had approved Global Blood Therapeutics’s drug, Oxbryta, to treat sickle cell disease in adults and pediatric patients aged 12 years or older. The disease is a lifelong, inherited blood disorder in which abnormally shaped red blood cells restrict flow of blood in vessels, leading to severe pain and organ damage. The drug, also known as voxelotor, aims to treat the underlying cause of sickle cell disease by preventing sickle cells from deforming. …read more […]

No Picture
Trading Ideas

Activist investor presses Valaris for broader changes, plans on special meeting

Hedge fund Luminus Management said on Monday that it plans to call a special shareholder meeting at Valaris PLC and press for broader improvements at the offshore contract drilling services company which promised its own changes two weeks ago. Valaris’ stock price surged 12% on Monday to trade at $4.40 after Luminus publicly called on the company to improve operations, refresh the board and shore up governance. The hedge fund also wants management to “take a holistic and balanced approach to managing (it’s) capital structure, with a specific focus on ensuring liquidity, pushing out debt maturities and effectively …read more […]